Author details

Full Name

Prahlad T Ram

Affiliation

ORCID

Career Start Year

1993

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37515726	Fluoride in groundwater of industrial town of Sonbhadra district, Uttar Pradesh, India: probable release mechanism and potential health risk assessment.		2023
36077735	Molecular Analysis of Short- versus Long-Term Survivors of High-Grade Serous Ovarian Carcinoma.	Cancers (Basel)	2022
36239936	Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics.	JAMA Netw Open	2022
34583979	Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models.	Mol Cancer Ther	2021
34293313	Potentially toxic elements in soil and road dust around Sonbhadra industrial region, Uttar Pradesh, India: Source apportionment and health risk assessment.	Environmental Research	2021
33793425	Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens.	JCI Insight	2021
33567287	Gain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype.	Cell Rep	2021
33551196	Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study.	Gynecol Oncol	2021
34341055	Editor's Note: Targeting Src in Mucinous Ovarian Carcinoma.	Clin Cancer Res	2021
34341054	Editor's Note: Biologic Effects of Platelet-Derived Growth Factor Receptor Î± Blockade in Uterine Cancer.	Clin Cancer Res	2021
34407412	CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance.	Cell Rep	2021
34391578	MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer.	Gynecol Oncol	2021
33087324	Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling.	Cancer Res	2020
30926640	GnRH-R-Targeted Lytic Peptide Sensitizes <i>BRCA</i> Wild-type Ovarian Cancer to PARP Inhibition.	Mol Cancer Ther	2019
30420565	Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4.	Mol Cancer Ther	2019
29661830	Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction.	Cancer Res	2018
29889660	Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens.	JCI Insight	2018
30050129	FABP4 as a key determinant of metastatic potential of ovarian cancer.	Nat Commun	2018
27669434	Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p.	Oncogene	2017
28814667	Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens.	JCI Insight	2017
28855350	Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression.	Clin Cancer Res	2017
27829138	Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth.	Cell Metab	2016
30234281	Surgical management and prognosis of perforation secondary to typhoid fever.	Tropical gastroenterology : official journal of the Digestive Diseases Foundation	2016
27287813	Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma.	J Pathol	2016
26920219	Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism.	Elife	2016
27041221	A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer.	Nat Commun	2016
26865225	Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer.	Oncogene	2016
27160903	Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer.	Cell Rep	2016
26581245	Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer.	Clin Cancer Res	2016
26505200	Robust Selection Algorithm (RSA) for Multi-Omic Biomarker Discovery; Integration with Functional Network Analysis to Identify miRNA Regulated Pathways in Multiple Cancers.	PLoS One	2015
28725457	Genome-wide perturbations by miRNAs map onto functional cellular pathways, identifying regulators of chromatin modifiers.	NPJ Syst Biol Appl	2015
25416196	Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer.	Clin Cancer Res	2015
25378249	Cupid: simultaneous reconstruction of microRNA-target and ceRNA networks.	Genome Res	2015
25629879	Corrigendum: A pan-cancer proteomic perspective on The Cancer Genome Atlas.	Nat Commun	2015
25873999	Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer.	Genome Med	2015
26081979	The ZNF304-integrin axis protects against anoikis in cancer.	Nat Commun	2015
24642504	Mapping network motif tunability and robustness in the design of synthetic signaling circuits.	PLoS ONE	2014
25490449	Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers.	Cancer Cell	2014
25297634	Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1Î± and oxidative phosphorylation in melanoma.	Cancer Res	2014
24183729	Platelet-derived growth factor receptor alpha (PDGFRÎ±) targeting and relevant biomarkers in ovarian carcinoma.	Gynecol Oncol	2014
24492837	Cancer Systems Biology: a peek into the future of patient care?	Nat Rev Clin Oncol	2014
24634380	Biologic effects of platelet-derived growth factor receptor Î± blockade in uterine cancer.	Clin Cancer Res	2014
24583248	A switch in the source of ATP production and a loss in capacity to perform glycolysis are hallmarks of hepatocyte failure in advance liver disease.	Journal of Hepatology	2014
25026212	Hematogenous metastasis of ovarian cancer: rethinking mode of spread.	Cancer Cell	2014
24799285	Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer.	Mol Syst Biol	2014
24619206	2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity.	Nat Commun	2014
24743243	Notch3 pathway alterations in ovarian cancer.	Cancer Res	2014
24871328	A pan-cancer proteomic perspective on The Cancer Genome Atlas.	Nat Commun	2014
23620404	Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47).	Clin Cancer Res	2013
24349639	Network Motifs in JNK Signaling.	Genes and Cancer	2013